rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-5-673-676rpcardio-966Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯTHE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR?ПРИМЕНЕНИЕ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА ПОСЛЕ ПЕРЕНЕСЕННОГО ИНФАРКТА МИОКАРДА. О ЧЕМ ГОВОРЯТ ДАННЫЕ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ?МарцевичС. Ю.MartsevichS. Yu.

101990 Москва, Петроверигский пер., 10

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Petroverigsky per. 10, Moscow, 101990 

Trubetskaya ul. 8/2, Moscow, 119991 

smartsevich@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины, Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияState Research Center for Preventive Medicine, I.M. Sechenov First Moscow State Medical UniversityRussian Federation20102201201665673676Copyright © Martsevich S.Y., 20162016Марцевич С.Ю.Martsevich S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/966

The main trails proven angiotensin converting enzyme (ACE) inhibitor effects on the life prognosis after myocardial infarction (MI) are described. Different tactics of ACE inhibitors therapy in post MI patients are presented. Approaches to the choice of a specific ACE inhibitor are discussed.

Описываются основные исследования, доказавшие влияние ингибиторов ангиотензинпревращающего фермента (АПФ) на прогноз жизни больных после инфаркта миокарда (ИМ). Представлены разные тактики назначения ингибиторов АПФ при ИМ. Обсуждаются вопросы, связанные с выбором конкретного ингибитора АПФ.

рандомизированные клинические исследованияингибитор ангиотензинпревращающего ферментаинфаркт миокардаrandomized clinical trialsangiotensin converting enzyme inhibitormyocardial infarctionReferencesPfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular disfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669-677.Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular disfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669-677.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect oframipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875): 821-828.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect oframipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875): 821-828.The TRACE Study Group. The TRAndalopril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994; 73(10): 44C-50C.The TRACE Study Group. The TRAndalopril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994; 73(10): 44C-50C.Swedberg K., Held P., Kjekhus J. et al. Effects of the early administration of enalapril on mortality in patients with myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study. N Engl J Med 1992; 327(10): 678-684.Swedberg K., Held P., Kjekhus J. et al. Effects of the early administration of enalapril on mortality in patients with myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study. N Engl J Med 1992; 327(10): 678-684.Ball S.G., HallA.S. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Am Heart J 1996; 132 (1 Pt 2 Su): 244-250.Ball S.G., HallA.S. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Am Heart J 1996; 132 (1 Pt 2 Su): 244-250.CCS-1. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951): 686-687.CCS-1. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951): 686-687.GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951): 669-685.ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345(8951): 669-685.Ambrosioni E., Borghi C., Magnani B., Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332(2): 80-85.Ambrosioni E., Borghi C., Magnani B., Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332(2): 80-85.Dickstein K., Kjekshus J., OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360(9335): 752-760.Dickstein K., Kjekshus J., OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360(9335): 752-760.Pfeffer M., McMurray J., Velazquez E. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893- 1906.Pfeffer M., McMurray J., Velazquez E. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893- 1906.Van de Werf F., Bax J., BetriuA. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29(23): 2909- 2945.Van de Werf F., Bax J., BetriuA. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29(23): 2909- 2945.Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28(13): 1598-1660.Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28(13): 1598-1660.Martsevich S., Lukina Y., Dmitrieva N. et al. Comparison of new generic and original ramipril in patients with arterial hypertension and high cardiovascular risk. Rational Pharmacother. Cardiol 2010; 6: 20-28. Russian (Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнение нового дженерика и оригинального препарата рамиприла у больных артериальной гипертонией и высоким риском сердечно-сосудистых осложнений. Рациональная Фармакотерапия в Кардиологии 2010; 6(1):20-28).Martsevich S., Lukina Y., Dmitrieva N. et al. Comparison of new generic and original ramipril in patients with arterial hypertension and high cardiovascular risk. Rational Pharmacother. Cardiol 2010; 6: 20-28. Russian (Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и др. Сравнение нового дженерика и оригинального препарата рамиприла у больных артериальной гипертонией и высоким риском сердечно-сосудистых осложнений. Рациональная Фармакотерапия в Кардиологии 2010; 6(1):20-28).

The authors declare that there are no conflicts of interest present.